The top 9 drugs currently under research and developments are ranked based on their Net Present Value. These drugs are forecasted to be the future blockbuster. With $10,199 million Net Present Value, Aducanumab, the Ant-Alzheimer's investigational drug of Biogen is ranked as the topmost valued upcoming drug under development. Total Word Counts of the article: 782. Continue reading..
A unicorn is a startup company with a current valuation of US$1 billion or more. In this post, Medgenera DATALABS has compiled data from 25 venture-backed private healthcare companies with post-money valuations of US $1 billion and more. Subscribe to read the full report.
With the latest equity financing of US $500M, Moderna is now the most valued healthcare unicorn startup in the world. The company is enabling messenger RNA science to develop a new generation of transformative medicines for patients with their Core “Expression” Platform: messenger RNA Therapeutics (a trademark platform). It has at least 10 candidates in Phase 1 or later stages of the clinical trials.
Ambitions to evolve and secure the future lead everyone to race against time. The changing lifestyle tampers with the health and fitness of an individual. Women’s reproductive efficiency is being significantly affected by this phenomenon. The whole scenario has given rise to an emerging market of assisted reproductive technology (ART). The global assisted reproductive technology market is expected to reach over 37 million USD by the end of 2025.